Árpád Szöőr

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

Gábor Tóth, Árpád Szöőr, L Simón et al. · mAbs · 2016 · 103 citations · Full text

Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies

Árpád Szöőr, Gábor Tóth, Barbara Zsebik et al. · Cancer Letters · 2020 · 97 citations · Full text

Breast Oncology, Immunology, Immunotherapy +16

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia

Challice L. Bonifant, Árpád Szöőr, David Torres et al. · Molecular Therapy · 2016 · 80 citations · Full text

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies

Mireya Paulina Velasquez, David Torres, Kota Iwahori et al. · Scientific Reports · 2016 · 56 citations · Full text

TCRs Genetically Linked to CD28 and CD3ε Do Not Mispair with Endogenous TCR Chains and Mediate Enhanced T Cell Persistence and Anti-Melanoma Activity

Coen Govers, Zsolt Sebestyén, Mandy van Brakel et al. · The Journal of Immunology · 2014 · 45 citations · Full text

T-regulatory Cell, Immunology, Immunologic Mechanism +19